CD74: HLA class II histocompatibility antigen gamma chain
Plays a critical role in MHC class II antigen processing by stabilizing peptide-free class II alpha/beta heterodimers in a complex soon after their synthesis and directing transport of the complex from the endoplasmic reticulum to the endosomal/lysosomal system where the antigen processing and binding of antigenic peptides to MHC class II takes place.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on CD74, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Milatuzumab | Phase 2 | Gilead Sciences | Antibody | AntagonistHLA-DR antigens-associated invariant chain antagonist | 0 |
- Non-small cell lung carcinoma0.63
- Neoplasm0.40
- Cancer0.39
- Lung adenocarcinoma0.38
- Squamous cell lung carcinoma0.38
- Lymphoid neoplasm0.37
- Acinar lung adenocarcinoma0.37
- Breast carcinoma0.30
- Acute myeloid leukemia0.30
- B-cell chronic lymphocytic leukemia0.30
- Diffuse large B-cell lymphoma0.29
- Pancreatic ductal adenocarcinoma0.29
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4692, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P04233, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets